Tag Archives: angiotensin-converting enzyme inhibitors
December 2020
Sacubitril-valsartan benefits in cancer therapy-related cardiac dysfunction
BJC Staff
The patients who developed cardiotoxicity were treated with beta blockers (carvedilol), angiotensin-converting enzyme inhibitors (enalapril) or angiotensin receptor blockers (valsartan), aldosterone antagonists (eplerenone), digitalis and diuretics (furosemide), as needed. When patients remained symptomatic and met the PARADIGM-HF inclusion criteria, sacubitril/valsartan was started instead of enalapril or valsartan. Results showed that sacubitril/valsartan therapy produced an improvement in ventricular remodelling, diastolic dysfunction, and on symptoms, reflected in the New York Heart Association class and the six-minute walk test. The auth
March 2013 Br J Cardiol 2013;20(suppl 1): S1–S16 doi:10.5837/bjc.2013.s01
Optimising hypertension treatment: NICE/BHS guideline implementation and audit for best practice
Dr Terry McCormack, Dr Chris Arden, Dr Alan Begg, Professor Mark Caulfield, Dr Kathryn Griffith, Ms Helen Williams
(more…)
September 2006 Br J Cardiol 2006;13:347-50
Should cardiologists be interested in albuminuria?
Clive Weston, Achanthodi Vasudev, Daniel Obaid, Saatehi Bandhopadhay, Jiten Vora
No content available
May 2005 Br J Cardiol 2005;12:240-3
Heart failure management in primary care – the story so far
Sarah Jarvis
No content available
May 2004 Br J Cardiol 2004;11:243-45
Angiotensin-converting enzyme inhibitor prescription for heart failure in general practice, and the impact of a Rapid Access Heart Failure Clinic in Cardiff
Pitt O Lim, Gary Lane, Jayne Morris-Thurgood, Michael P Frenneaux
No content available
September 2002 Br J Cardiol 2002;9:481-7
GP use of beta blockers in heart failure
Mike Mead
No content available
For healthcare professionals only
